Compositions and use of varenicline for treating dry eye

A nasal spray bottle containing an aqueous liquid pharmaceutical formulation for administration into a nasal cavity of a human, the formulation comprising a solution of varenicline or a pharmaceutically acceptable varenicline salt and one or more pharmaceutically acceptable inactive ingredients, wherein varenicline is the single therapeutic agent in the formulation, the concentration of varenicline in the formulation is between about 0.1 mg/mL and about 2 mg/mL, and one spray of the formulation from the bottle contains between 10 micrograms and 50 micrograms of varenicline.